



September 07, 2005 02:38 PM US Central Timezone

VasoGenix Pharmaceuticals Announces Formation of Cardiology Research Steering Committee Through the Cleveland Clinic

LENEXA, Kan.--(BUSINESS WIRE)--Sept. 7, 2005--VasoGenix Pharmaceuticals, Inc. announces that, through the Cleveland Clinic Cardiovascular Coordination Center, a Research Steering Committee has been constituted. The purpose of the Steering Committee is to assist the company in focusing its clinical research plan for the company's cardiology drug, Calcitonin Gene Related Peptide (CGRP). The Steering Committee is composed of leading American and international clinical cardiologists and scientists. The Cleveland Clinic, America's #1 Heart Center, will be the lead institution in the implementation of the clinical trial plan.

Commenting on the committee's formation, G. Lee Southard, Ph.D., Chairman and CEO, stated: "Our business model calls for teaming with the best available Clinical and Academic Research Organizations and we are pleased to be working with the Cleveland Clinic and this outstanding Research Steering Committee. This action is consistent with our mission of developing critical-need cardiology products that are maximally beneficial to patients and to the cardiologists who treat them. CGRP has a mechanism of action and a clinical human safety data profile suggesting potential application in several important cardiology applications. In addition CGRP has a demonstrated natural cardioprotectant profile and in humans has demonstrated a positive hemodynamic profile. The plan that emerges from the Research Steering Committee will assist the company in prioritizing and focusing its remaining pre-clinical activities and the submission of a timely and quality IND (Investigational New Drug) application to the FDA."

VasoGenix is a pharmaceutical company focused on the development of a pipeline of cardiology products based on its proprietary position with Calcitonin Gene Related Peptide (CGRP). Among these potential products are the treatment of Myocardial Infarction (MI) and Congestive Heart Failure (CHF). MI is America's #1 killer for both men and women. CHF is one of America's most morbid diseases for people over 65 and is America's #1 medical expense estimated at \$38 billion. For more information on VasoGenix Pharmaceuticals Inc. and to learn more about CGRP visit the company web site at <http://www.vasogenix.net>.